INCA33890 + bevacizumab + leucovorin + fluorouracil + oxaliplatin

This drug is a **combination therapy** comprising INCA33890 (a bispecific monoclonal antibody immunotherapy), bevacizumab (a humanized monoclonal antibody targeting vascular endothelial growth factor A, VEGF-A), leucovorin (folinic acid, an adjuvant enhancing fluorouracil’s effectiveness), fluorouracil (a pyrimidine analog antimetabolite inhibiting thymidylate synthase), and oxaliplatin (a platinum-based cytotoxic chemotherapy agent). INCA33890 is designed to activate the immune system and inhibit cancer cell survival, with known targets being TGFbetaR2 and PD-1. This combination is utilized or under investigation for advanced or metastatic solid tumors, including breast, lung, colorectal, ovarian, pancreatic, melanoma, and other solid cancers[1][3][5][4][2]. The therapy combines immunomodulation, anti-angiogenesis, and cytotoxic antineoplastic effects, delivered by intravenous infusion.

Other names

leucovorinfluorouraciloxaliplatin